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Comment to “The outcome of peripheral T-cell 
lymphoma patients failing first-line therapy”
Bellei et al. must be congratulated for their recent study
presenting a thorough work-up of the “real-world” out-
come of patients with peripheral T-cell lymphoma
(PTCL) who have failed first-line chemotherapy.1 Among
other findings, they elegantly address the question as to
whether hematopoietic cell transplantation (HCT) can
alter the dismal natural course of relapsed or refractory
(R/R) PTCL. In contrast to previous studies following a
similar design,2,3 Bellei et al. were able to compare
patients actually receiving HCT with those who were
sensitive to salvage chemotherapy but not eligible for
HCT, and with patients who were chemosensitive and
eligible for HCT but who did not undergo HCT for any
reason. The results suggest that it is indeed the HCT
itself that provides the greatest survival benefit, rather
than being transplant eligible or having chemosensitive
disease.1 
To fully understand the implications of these findings,
however, two issues need some additional explanation.
The first is the question of how transplant ineligibility
was defined, and what the reasons were for not proceed-
ing to HCT in chemosensitive transplant-eligible
patients. The second question is related to the type of
HCT. Since autologous and allogeneic transplantation
represent two fundamentally different biological princi-
ples, with different efficacy in patients with R/R PTCL,2,3
it seems of paramount importance to add information
about which type of HCT was used in this study. The
most likely scenario is that both types were used; in that
case, a comparison by the type of transplant would be
mandatory in order to help guide rational (and potential-
ly life-saving) decision-making in this otherwise
extremely unfavorable condition. 
Peter Dreger
Department of Medicine V, University of Heidelberg, Germany
Correspondence: PETER DREGER. 
peter.dreger@med.uni-heidelberg.de  
doi:10.3324/haematol.2018.206904
Information on authorship, contributions, and financial & other disclo-
sures was provided by the authors and is available with the online ver-
sion of this article at www.haematologica.org.
References
1. Bellei M, Foss FM, Shustov AR, et al. The outcome of peripheral T-
cell lymphoma patients failing first-line therapy: a report from the
prospective, International T-Cell Project. Haematologica. 2018;
103(7):1191-1197.
2. Chihara D, Fanale MA, Miranda RN, et al. The survival outcome of
patients with relapsed/refractory peripheral T-cell lymphoma-not
otherwise specified and angioimmunoblastic T-cell lymphoma. Br J
Haematol. 2017;176(5):750-758.
3. Rohlfing S, Dietrich S, Witzens-Harig M, et al. The impact of stem
cell transplantation on the natural course of peripheral T-cell lym-
phoma: a real-world experience. Ann Hematol. 2018;97(7):1241-
1250.
The outcome of peripheral T-cell lymphoma patients
failing first-line therapy: a report from the 
prospective International T-Cell Project
We are grateful to Peter Dreger for his comments1 on
our study focusing on the outcome of patients with
peripheral T-cell lymphoma registered in the prospective
International T-Cell Project who failed first-line
chemotherapy.2 The author recognizes the thorough
work-up that has been carried out and reported in the
paper, but has asked for additional details on the follow-
ing two issues: i) how transplant ineligibility was defined
and what were the reasons for not proceeding to
hematopoietic cell transplantation (HCT) in chemosensi-
tive, transplant-eligible patients; and ii) which type of
transplant the patients analyzed received: autologous or
allogeneic.
The T-Cell Project is totally an academic effort and not
a sponsored clinical trial. This means that some informa-
tion, such as eligibility for transplant, was collected in a
very simple way, based on the treating physician’s deci-
sion according to local guidelines. Moreover, our data-
base did not capture data about the reason why the local
physician did not put chemosensitive, transplant-eligible
patients forward for HCT; although we cannot exclude
the possibility that, in some instances, the availability of
new drugs could have determined the clinician’s decision
to enroll the patients in ongoing interventional clinical
trials. 
With respect to the type of transplant: 76 (77%), 18
(18%) and 5 (5%) patients went forward for autologous,
allogeneic myeloablative and allogeneic non-myeloabla-
tive transplantation, respectively. We conducted some
additional analyses in order to rule out any bias accord-
ing to the value of the two different types of transplant;
however, the limited number of patients who went for-
ward to allogeneic transplant did not allow us to reach
any robust conclusions. Thus, no data on the topic were
provided in the paper.
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